Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Last post: denby69, 13 Dec 2022 10:36
chicken lol No1 it only costs 9 squids to trade ABCM and abcm might be just taken over + plus the NDAQ is down so much its got to be worth a punt, have a good as the saying goes lol.
True, couldn’t find their charges . Suspect they are reasonable though. The ft are talking about M&As dropping off but with the SP of many good companies down I think there may well be some raids happening in the first quarter of 2023. Just my thoughts.
Ive also decided not to invest overseas as I don’t want to take on the extra risk with foreign ex movements. :-).
thhey have still have FCA protection
Trading 212 us to be called Avus which was run by 2 Bulgarians. Who ceased directorships . Trading 212 operate out of Bulgaria and Cyprus. They are probably ok but the mention of Bulgaria and Cyprus put me right off. ;-).
AJ bell. I use to use Bestinvest but they are rubbish. Although they didn’t charge to switch funds. Finding AJ bell quite good so far. Also been leaning towards trackers but it’s all a it of a guessing game as fund managers seem to be in a lot of cases lucky than experts. :-)
got a few to day near the bottom just another dollar down and think we might be at the bottom.
Started: denby69, 6 Dec 2022 15:41
Last post: denby69, 7 Dec 2022 16:59
I believe that this will be taken over and I am still buying I only have 7.6k shares.
The delisting, I think happens on 14 December. I have bought another decent tranche of shares today to double my holding. Time will determine the wisdom or folly.
ABC are not doing very well since the move to the states in full
Started: Alas_Smith, 22 Nov 2022 23:40
Last post: Alas_Smith, 30 Nov 2022 21:45
As the Fed has hinted that interest rates will not be as aggressive as in the past with the next rise close to a 0.5% increase, markets have responded positively, particularly the NASDAQ today. And although I am conscious that many retail investors like to believe that their portfolio is diverse, geographic exposure provides depth. Sure, for many AIM can seem a little wild, but compared with the NASDAQ is a lamb.
Fortunately ABC is already listed across the swamp. Perhaps the only real differences seen by holders based in UK (and Europe) will be in dealing times that do not correspond with London and fewer contributions here.
With shares only having a single listing once cancelled, my only concern in the short term is in regards to fund managers moving holdings between portfolio’s in their ****nal to bring volatility. Long term should be better and not tarnished with any reputational damage that AIM might have for investors.
Last post: denby69, 30 Nov 2022 10:29
Alas_Smith,SussexEngineer. the last week T sold my entire holding in ABC, FOR 1466. and bought back in @ 1250 + I Increased my holding by a third . I go with the BOD on their decision, to move to a single listing in the states my personal view this can only be good for ABC. ABC might even be taken over, but I hope not.
Although I am not in the least qualified to provide advice and certainly would not criticise anothers decision, I will caution others with, I hope, a reasoned and broad response.
The most influential economy in the world is US. The largest companies by MCap are in the US and the dollar is the rate against which every commodity is priced. In other words, just because it is dealt in, based in or trades from USA means that it is a bit more important than all the other exchanges in the World. Sure, London is right up there, so is Paris, Frankfurt, Melbourne and Tokyo but as economies go, US then China, India, Europe etc down the pecking order.
FWIW, my portfolio from 1979 until 2008 was entirely UK specific (I knew nothing else and considered nothing beyond UK shores). Around 60% portfolio is US/China based these days and although down a long way this year (-22.x%), recovery when this bear market is over is likely to be greater than if there was a concentration in a single market.
Good fortune to all. 2023 has more turbulence ahead as I foresee OPEC cutting production to deepen recession for UK. Another thought to consider different geographic sector to place investment deposits.
Shame that management have moved the share dealings solely to the States, when 90% are on the LSE. I decided to pull my shares on the back of this.
I agree it a great business, well run with a fantastic future but in the short term plenty of long term holders like me will have pulled the plug.
Alas_Smith I do think that your views about ABC are spot on. It still seems to expanding with all the head winds that are around at the moment, it just seems a bit over done with a drop of 13.50% just due to share sales, share shifting by fund managers. this company is well run and as you said have excellent management. just think is this is well over done.
I believe it is all part and parcel of those funds re-arranging their holdings. As the underlying business is good and the managers excellent, I am not in the least fussed with what is, to all intents and purpose, noise.
Started: denby69, 28 Nov 2022 14:29
Last post: denby69, 28 Nov 2022 14:29
this will keep going until she goes over
NanoString Technologies (NASDAQ:NSTG) and Abcam (NASDAQ:ABCM) said they expanded their collaboration to advance spatial multiomics research.
Under the agreement, the companies will co-market Abcam antibodies for NanoString's high-plex spatial multiomic solutions.
Abcam RabMAb recombinant antibodies will be commercialized as part of the first 64-plex protein panel for NanoString's CosMx Spatial Molecular Imager (SMI).
"This relationship will further expand the depth and breadth of spatial biology offerings on NanoString instrumentation into new frontiers of human biology down to single-cell resolution— a true revolution in the spatial biology field," said NanoString President and CEO Brad Gray.
Started: denby69, 6 Oct 2022 11:56
Last post: denby69, 10 Oct 2022 13:09
MIGHT come in again when we get to 1290-1300
SOLD OUT may have made more as it is leaving AIM but 30% profit and happy with that.
Started: SussexEngineer, 12 Sep 2022 18:20
Last post: denby69, 12 Sep 2022 21:11
should do well on the Nasdaq
Good to see strong growth and margins but disappointing operating profit, on the back of rising operating costs/expenses and greater R & D expenditure. Again no mention of dividends which to say the least is disappointing for LTH's. The cash holdings now almost match the company debts which again makes the lack of a dividend surprising. I can only think that either the money is ready for another acquisition or more likely a sweetener for the planned pull out from the FTSE AIM and sole listing on the US Nasdaq market.
LIKE a yo-yo to day lol
Started: SussexEngineer, 20 Jul 2022 18:18
Last post: Bluechiplet, 25 Jul 2022 09:28
The same thing happend with Amryt Pharma in November last year. Barclays at that time said they couldn't hold Nasdaq ADRs in an ISA Account. From what others have written this may not have been quite accurate. I then checked the position regarding selling and rebuying in a SIPP account (not with Barclays). I was informed that you can hold ADRs in a SIPP, but that you wouldn't be able to trade them as per a 'normal' share. I chose to sell Amryt, rebought in a nominee account and waited for them to be converted to ADRs. That transfer was pretty straighforward. The subsequent drop in the Nasdaq has meant that actually the better plan would simply have been to sell the holding! Also, just to note, there are tax implications with such holdings held overseas (assuming they go up...lol)
I forget the precise figures, but from what I remember Amryt justified the transfer to remove the cost of the dual listing and that c90% of trades in any one day were on the Nasdaq exchange.
Sadly, I suspect more companies will choose to follow Abcam simply because there is a far larger market in the US for trading shares. Given this possibility, I equally suspect more brokers ( and regulators) will in time facilitate the process to transfer holdings in order to not lose out on investments that move overseas.
My SIPP is with Fidelity. Can only hold foreign shares in an ISA or Investment Account. Pretty upset but total understand why they want to clear off abroad. May take a similar stance myself when Truss comes to Office.
To keep you all in the loop and to save Abcam the hassle of responding to everyone here is my response from them:
"...the Board of Directors have decided to pursue a sole listing on NASDAQ and will continue consulting with shareholders for approval to delist from AIM at a General Meeting later this year. Today, our shares are convertible on a 1:1 basis from AIM to American Depository Shares (ADSs) listed on NASDAQ. If we were to go through the process of delisting, in line with precedent, we anticipate there to be mechanisms in place to facilitate this conversion and support existing AIM ordinary shareholders.
We will continue to communicate with all shareholders in the coming months and will provide further details of the impact and the options available to all shareholders, including the publication of a circular which will cover all material information on the specifics on the matter, ahead of an expected shareholder vote later in the year."
Trouts, I contacted my provider and they said they are waiting on further information from Abcam before offering advice and actions.
Most SIPP providers will happily let you hold US shares in your account. You'll need to complete a W-8BEN (US tax) form to avoid being stung on taxes (your provider should have one online). It may be worth contacting them to see if they are making special arrangements for the transfer.
Started: denby69, 21 Jul 2022 10:08
Last post: denby69, 21 Jul 2022 10:08
looks like a good move for ABC to get away from this country and of AIM might get to TRUE VALUE
Started: denby69, 21 Jun 2022 09:20
Last post: denby69, 21 Jun 2022 09:20
and this bb is not running lol just like abcam going down the toilet lol
Started: denby69, 27 Apr 2022 16:56
Last post: denby69, 15 Jun 2022 14:05
well i HAVE CLOSED MY LAST SHORT today @ 10.97 quite happy with the profit :-)
2nd short closed
SHORT OFF LOLP
denby69 - what drivel.
THE SP on this site is not accurate this is as I have said before highly manipulated
and not really worth logging in to
About time rbc got their act together and this donky started to rise, Thank GOD I have got gsk
Started: denby69, 4 Feb 2022 08:44
Last post: denby69, 8 Feb 2022 10:03
lordloadsoflolly,
Even though you have ****ged me off i have agreed with you twice :-0
There are fewer surer ways to lose money than by following broker ratings IMHO. Brokers & analysts nearly always have a vested interest (either holding the shares they comment on or being paid by the client to conduct "research"). When things don't go to plan, they simply change their mind, adjusting their recommendation from a strong buy to a hold or even an avoid. Do your own research then follow your gut instinct. But unless you've money to burn, it very rarely pays to heed brokers or analysts.
alphawave should move up tomorrow morning Denby.
look at all the brokers ratings lordloadsoflolly lol
denby69 - re: your last post "you should never pay attention to what people post". Don't worry - in your case, nobody does.
Started: denby69, 2 Feb 2022 09:16
Last post: denby69, 2 Feb 2022 09:16
we need to break the 1362 and 1420 to start going back to where we belong. :-)
we need to stay above 1292 for a few days
Started: denby69, 27 Jan 2022 12:13
Last post: SussexEngineer, 27 Jan 2022 13:27
The delay is due to the US shareholders, so that they are not at an undue disadvantage.
Results were solid. Growth was as largely predicted. The one good element was the acquisition of BioVision is showing sound reasoning, with a growth rate higher than the existing portfolio.
Planned 2024 performance is inline with expectations, despite the Covid impact that has affected customers over the last 21 months.
Hoping to see a rise from here.
I think they are good see below
27 January 2022
27 January 2022
ABCAM PLC
Trading Update
Cambridge, UK: Abcam plc ("Abcam", "Company", "Group") (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update ahead of reporting its financial results in March:
The Group expects to report total revenues for the 12 months ended 31 December 2021 of approximately £315 million, representing growth of over 22% on a constant exchange rate (CER) basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition's completion on 27 October 2021.
Revenue growth continues to be driven by demand for the Company's proprietary products, with in-house catalogue sales up approximately 37% CER on an organic basis (43% including BioVision), together with a continued recovery in global lab activity. Whilst risks related to the pandemic remain - as evidenced by the emergence of the Omicron variant in late 2021 - data indicates that, while not yet returning to pre-covid levels, overall lab activity continued to increase through 2021.
The Group has continued to build capabilities, invest in innovation and implement its multi-year growth strategy throughout the period. Overall, we anticipate adjusted operating profits will be reported in line with the board's expectations for the period and we remain on track to achieve our financial goals for the five year plan ending in 2024.
Following the change in the Company's financial year end to 31 December, full results for the 18 month period ended 31 December 2021 will be released on 14 March 2022. In order to aid comparison, pro forma information for the 12 month periods ended 31 December 2021 and 31 December 2020 will also be provided.
Alan Hirzel, CEO of Abcam commented:
"2021 was a year of significant innovation and growth in proteomic tools and discovery. I thank our customers for trusting Abcam as their preferred partner and our global colleagues for their unwavering dedication to customer needs and aspirations. Together, we are building a durable enterprise that is making a difference in the pace and social impact of discovery. I am confident in our progress toward our 2024 business goals and I look forward to providing the full update in March."
1 Incremental revenue excludes sales of BioVision products through Abcam channels
This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.
Abcam plc
+ 44 (0) 1223 696 000
James Staveley, VP Investor Relations
Numis - Nominated Adviser & Joint Corporate Broker
+ 44 (0) 20 7260 1000
Garry Levin / Freddie Barnfield / Duncan Monteith
Morgan Stanley - Joint Corporate Broker
+ 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI C
Last post: denby69, 27 Jan 2022 11:06
On Trading view update says 6 of march on this site it said last week trading up date TODAY
YOU cant trust anybody lol
Last post: denby69, 27 Jan 2022 08:36
guess the trading statement is where boris s party results are LOL
Last post: denby69, 26 Jan 2022 19:47
might see some fun and games to-morrow
Started: denby69, 26 Jan 2022 08:41
Last post: denby69, 26 Jan 2022 09:03
good download
what do you all think??
https://www.londonstockexchange.com › stock › ABC › abcam-plc › company-page
WE NEED TO CLOSE @ 12.97 OR OVER and hold for a day then up to 13 28---1349 and smash this resistance
Last post: denby69, 25 Jan 2022 12:05
did not expect the 1190s yesterday but still trading statement Thursday according to this site. orders have increased but profit has taken a dip, just a waiting game until it is back up to 1600
Denby, I do hope so. As they have switched their annual reporting from June to December, it was important to understand Abcam's progress, especially after the acquisition of BioVision.
Just wondering if it is safe to take flak jacket off yet..... Yesterday was pretty brutal.
trading statement Thursday :-)